Evofem initiated with an Overweight at Cantor Fitzgerald. Cantor Fitzgerald analyst William Tanner started Evofem Biosciences with an Overweight rating and $9 price target. The analyst believes the company’s multi-purpose vaginal pH regulator technology will aid in the creation of novel products for women.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.